Morbid Obesity Clinical Trials 2022

Browse 27 Morbid Obesity Medical Studies Across 33 Cities

1 Phase 3 Trial · 39 Morbid Obesity Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Single-anastomosis Duodenal Switchfor Obesity

Quebec City, Canada
18 - 65
All Sexes
Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question. Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies. With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.
Waitlist Available
Has No Placebo
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

BWLTfor Obesity

Calgary, Canada
18+
All Sexes
Psoriatic Arthritis (PsA) is a type of auto-immune condition that affects roughly 90,000 Canadians. Patients with PsA often experience joint pain, skin problems, and issues with mobility that negatively impact their quality of life. Compared to the general population, patients with PsA are at a higher risk of having obesity (excess body weight). Although there is no cure for PsA, medications can be helpful for symptoms, and weight loss can provide an added benefit to the effectiveness of medications. Behavioral weight loss treatment (BWLT) is a proven way to lose weight and keep it off. BWLT usually includes individual or group sessions with a health professional to learn strategies and tools to change behaviours and thoughts in order to support weight loss. However, few studies have designed a BWLT with the unique needs of patients with PsA in mind. Before testing new treatments for chronic disease in large, expensive studies, it is important to do smaller-scale research to make sure that a future large study will be successful. In line with this, the objective of our study is to test the feasibility of a future, large study of a BWLT for patients with PsA and obesity. In other words, our small feasibility study will investigate how convenient, reasonable, and acceptable the future study's procedures are, using a small group of people with PsA and obesity. People who have PsA and obesity will take either a special BWLT program, or receive usual care for PsA from a community-based rheumatologist. Those in the BWLT group will complete 16 online group sessions to help them learn cognitive and behavioral changes to help improve their health and manage weight. After 24 weeks, we will determine study completion rates, examine patient satisfaction, and assess whether the BWLT was provided to people as-designed. We believe this research will help with efforts to provide more effective treatments to patients with PsA to help them lose weight and improve their quality of life through reduced pain and symptoms.
Phase 1
Recruiting
25 Morbid Obesity Clinical Trials Near Me
Winston-Salem, NC
Morgantown, WV
Quebec City, Canada
Salt Lake City, UT
More Trial Locations
An interactive map to display trial locations for Wake Forest University Health Sciences, West Virginia University, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Bariatric Medicine Institute, and 23 more locations.
Most Popular References for Morbid Obesity Clinical Trials
Frequency
Citation
Top Hospitals for Morbid Obesity Clinical Trials
Location
Active Morbid Obesity Clinical Trials
All Time Trials for Morbid Obesity
First Recorded Morbid Obesity Trial
Trials
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec
2
2
2015
Wake Forest University Health Sciences, Winston-Salem, North Carolina
1
1
2022
West Virginia University, Morgantown, West Virginia
1
1
2022
Bariatric Medicine Institute, Salt Lake City, Utah
1
1
2021
University of Missouri-Columbia, Columbia, Missouri
1
1
2021
Top Treatments for Morbid Obesity Clinical Trials
Treatment Name
Active Morbid Obesity Clinical Trials
All Time Trials for Morbid Obesity
First Recorded Morbid Obesity Trial
Trials
Endolumik Gastric Calibration Tube (EGCT)
1
1
2022
Single-anastomosis duodenal switch
1
1
2022
Self Forming Magnets (SFM)
1
1
2021
Top Cities for Morbid Obesity Clinical Trials
City
Active Morbid Obesity Clinical Trials
Top Active Site for Morbid Obesity Clinical Trials
Trial List
Quebec City, Quebec
2
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Columbia, Missouri
2
University of Missouri-Columbia
Houston, Texas
2
Memorial Hermann Texas Medical Center
San Francisco, California
2
University of California San Francisco
Which phases are most popular for morbid obesity clinical trials?
Most Recent Morbid Obesity Clinical Trials
Phase 3 Morbid Obesity Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
7/1/2008
Phase 3
Pediatric Morbid Obesity Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Senior Friendly Morbid Obesity Clinical Trials
Recently Completed Studies with FDA Approved Treatments for Morbid Obesity
Treatment
Year
Mechanism of Action
Sponsor
Active Morbid Obesity Clinical Trials
Phentermine
2020
Phentermine
Jaime Moore, MD MPH
0

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: August 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.